{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:53:16Z","timestamp":1791604396175,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC1846"],"award-info":[{"award-number":["2023NSFSC1846"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","award":["2024LZXNYDJ024"],"award-info":[{"award-number":["2024LZXNYDJ024"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903000"],"award-info":[{"award-number":["81903000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201682"],"award-info":[{"award-number":["81201682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032579","name":"Beijing Medical Award Foundation","doi-asserted-by":"publisher","award":["H21030"],"award-info":[{"award-number":["H21030"]}],"id":[{"id":"10.13039\/100032579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cllc.2026.08.012","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:03:35Z","timestamp":1787673815000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SBRT Plus Nivolumab in Advanced NSCLC: A Phase II Multicenter Study With Exploratory Bone Metastases Subgroup Analysis"],"prefix":"10.1016","volume":"27","author":[{"given":"Yuhao","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pang","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiya","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenming","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.cllc.2026.08.012_bib0001","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.012_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.cllc.2026.08.012_bib0003","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.08.012_bib0004","article-title":"Three-year follow-up from CheckMate 017\/057: nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Font","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2026.08.012_bib0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.08.012_bib0006","first-page":"2018","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.012_bib0007","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.012_bib0008","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"20","key":"10.1016\/j.cllc.2026.08.012_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011061","article-title":"The abscopal effect: a review of pre-clinical and clinical advances","volume":"22","author":"Janopaul-Naylor","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.012_bib0010","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.21037\/tlcr-20-1117","article-title":"A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer","volume":"10","author":"Akanda","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"10.1016\/j.cllc.2026.08.012_bib0011","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cac2.12316","article-title":"The theory of tumor ecosystem","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.012_bib0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cllc.2026.08.012_bib0013","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2022.03.006","article-title":"Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays \u201ccold\u201d immune characteristics in non-small cell lung cancer","volume":"166","author":"Zhu","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.08.012_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.012_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.cllc.2026.08.012_bib0016","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1097\/JTO.0b013e3181bbf223","article-title":"Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice","volume":"4","author":"Girard","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.012_bib0017","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.21037\/jtd-2019-cptn-07","article-title":"Radiation and immunotherapy: emerging mechanisms of synergy","volume":"12","author":"Breen","year":"2020","journal-title":"J Thorac Dis"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.012_bib0018","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 restrains radiotherapy-induced abscopal effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"18","key":"10.1016\/j.cllc.2026.08.012_bib0019","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1158\/1078-0432.CCR-16-2842","article-title":"Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.012_bib0020","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/annonc\/mdy408","article-title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.012_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000332","article-title":"Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity","volume":"3","author":"Yoo","year":"2018","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.012_bib0022","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.012_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.012_bib0024","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2026.08.012_bib0025","unstructured":"PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A pilot study (PRIME_LUNG). 2022. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05222087. Accessed June 19, 2026."},{"key":"10.1016\/j.cllc.2026.08.012_bib0026","unstructured":"Maintenance chemotherapy with or without local consolidative therapy in treating patients with stage IV non-small cell lung cancer. 2017. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03137771. Accessed June 19, 2026."},{"key":"10.1016\/j.cllc.2026.08.012_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103643","article-title":"Definitive radiotherapy to the primary tumor in stage IV NSCLC: a consensus statement from the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","author":"McMahon","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.08.012_bib0028","article-title":"Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: current status, possible mechanisms and application prospects","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.012_bib0029","doi-asserted-by":"crossref","first-page":"87","DOI":"10.21037\/tlcr-21-1033","article-title":"Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study","volume":"11","author":"Qiang","year":"2022","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.012_bib0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-021-01905-3","article-title":"Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial","volume":"16","author":"Ni","year":"2021","journal-title":"Radiat Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.012_bib0031","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41577-023-00836-2","article-title":"Locally sourced: site-specific immune barriers to metastasis","volume":"23","author":"Correia","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.012_bib0032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell Mol Immunol."},{"key":"10.1016\/j.cllc.2026.08.012_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697298","article-title":"Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio","volume":"12","author":"Bongiovanni","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.012_bib0034","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2026.08.012_bib0035","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fonc.2018.00612","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation","volume":"8","author":"Buchwald","year":"2018","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.012_bib0036","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.cllc.2026.08.012_bib0037","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.012_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.484","article-title":"Radiation therapy for palliation of symptomatic bone metastases: an ASTRO clinical practice guideline","volume":"120","author":"Alcorn","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.012_bib0039","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0360-3016(98)00264-8","article-title":"Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration","volume":"42","author":"Arcangeli","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.cllc.2026.08.012_bib0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3892\/ol.2023.13740","article-title":"Pretreatment levels of serum alkaline phosphatase are associated with the prognosis of patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"25","author":"Yang","year":"2023","journal-title":"Oncol Letters"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.012_bib0041","article-title":"A cross-sectional National Health and Nutrition Examination survey-based study of the association between systemic immune-inflammation index and blood urea nitrogen levels in United States adolescents","volume":"14","author":"Guo","year":"2024","journal-title":"Sci Rep"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:26:02Z","timestamp":1791602762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525730426001166"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.012","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SBRT Plus Nivolumab in Advanced NSCLC: A Phase II Multicenter Study With Exploratory Bone Metastases Subgroup Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}